Keyphrases
Israel
100%
COVID-19
73%
Streptococcus Pneumoniae
45%
Healthcare Workers
43%
BNT162b2 Vaccine
34%
Neutralizing Antibodies
33%
Staphylococcus Aureus
31%
Invasive Pneumococcal Disease
31%
BNT162b2
30%
PCV7
28%
Immunogenicity
27%
13-valent Pneumococcal Conjugate Vaccine (PCV13)
23%
Pneumococcal Conjugate Vaccine
20%
Vaccination
19%
Vaccine Dose
18%
COVID-19 Vaccine
18%
S. Pneumoniae
18%
COVID-19 Vaccination
17%
Medical Center
16%
Breakthrough Infection
15%
Third Dose
14%
Confidence Interval
14%
Immune Response
14%
Prospective Cohort Study
14%
Nationwide Surveillance
13%
SHEBA
13%
IgG Antibody
13%
BA.1
13%
Second Dose
13%
CA-MRSA
13%
Staphylococcus Aureus Carriage
13%
Risk Factors
12%
BA.5
12%
Omicron Variant
12%
Israeli
11%
Pregnant Women
11%
S. Aureus Carriage
11%
Methicillin-resistant Staphylococcus Aureus
10%
IgG Levels
9%
Surveillance Studies
9%
Odds Ratio
9%
Receptor-binding Domain
9%
Two-dose
9%
Humoral Response
8%
Unvaccinated
8%
Pili
8%
Vaccine Types
8%
COVID-19 Infection
8%
SARS-CoV-2 Infection
8%
Revaccination
8%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
54%
COVID-19
49%
Serotype
44%
Streptococcus pneumonia
44%
Staphylococcus Aureus
38%
Neutralizing Antibody
32%
Omicron Coronavirus Variant
27%
Pneumococcal Vaccine
26%
Methicillin-Resistant Staphylococcus Aureus
21%
Prevalence
19%
Pneumococcus
18%
Antibody Titer
17%
Immune Response
16%
Humoral Immunity
15%
Breakthrough Infection
15%
Neutralization
12%
Antibody Response
12%
Immunogenicity
12%
Comorbidity
12%
Immunoglobulin G
11%
Receptor Binding
10%
Penicillin
9%
Pilus
9%
Immunoglobulin G Antibody
8%
Titer
8%
Dynamics
8%
Wild Type
7%
Antimicrobial Resistance
7%
Coronavirinae
6%
Hydrogen Peroxide
6%
Upper Respiratory Tract
5%
Severe Acute Respiratory Syndrome
5%
Infectious Agent
5%
Spike
5%
Carbapenemase Producing Enterobacteriaceae
5%
Seropositivity
5%
Medicine and Dentistry
Severe Acute Respiratory Syndrome Coronavirus 2
58%
Infection
52%
COVID-19
49%
Pneumococcal Infection
26%
Serotype
21%
Diseases
20%
Pneumococcal Pneumonia
19%
Streptococcus pneumonia
19%
Health Care
17%
Neutralizing Antibody
16%
Messenger RNA
15%
Staphylococcus Aureus
12%
Immunoglobulin G
12%
Antibody Response
12%
Prospective Cohort Study
11%
Pneumococcus Vaccine
11%
Humoral Immunity
11%
Neutralization
10%
Coronavirinae
9%
COVID-19 Vaccine
9%
Immune Response
9%
Emergency Department
9%
Receptor Binding
9%
Adverse Event
7%
Household
7%
Observational Study
7%
Pneumococcus
7%
Immunoglobulin G Antibody
7%
Comorbidity
7%
Immunoglobulin A
6%
Primary Health Care
6%
Antibiotic Resistance
6%
Obstetrics
6%
Triage
5%
COVID-19 Vaccination
5%
Neonatal Infant
5%
Antibiotic Therapy
5%
Methicillin Resistant Staphylococcus Aureus
5%
Omicron Coronavirus Variant
5%
Retrospective Study
5%
West Nile Virus
5%
Severe Acute Respiratory Syndrome
5%
Immunosuppressive Treatment
5%